The safety profiles of several commonly used advanced therapies for Crohn’s disease appear similar, with no significant differences observed in risks for serious infections and cardiovascular adverse ...
Setmelanotide receives FDA approval for acquired hypothalamic obesity based on phase 3 trial data demonstrating meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results